Urogen Pharma (URGN) has provided an announcement.
UroGen Pharma Ltd.’s shareholders convened for their 2024 Annual Meeting, where they passed significant resolutions including the approval of the 2024 Non-Employee Director and Officer Compensation Policy and an expansion of the 2017 Equity Incentive Plan by 800,000 shares. Eight directors were elected, each to serve until the next annual meeting. Additionally, shareholders endorsed the executive officers’ compensation and appointed PricewaterhouseCoopers LLP as the independent auditor for the upcoming year, reflecting a proactive stance in shaping the company’s governance and incentive structures.
See more data about URGN stock on TipRanks’ Stock Analysis page.
